Literature DB >> 22582115

Activity and inhibition of prostasin and matriptase on apical and basolateral surfaces of human airway epithelial cells.

Shilpa Nimishakavi1, Marina Besprozvannaya, Wilfred W Raymond, Charles S Craik, Dieter C Gruenert, George H Caughey.   

Abstract

Prostasin is a membrane-anchored protease expressed in airway epithelium, where it stimulates salt and water uptake by cleaving the epithelial Na(+) channel (ENaC). Prostasin is activated by another transmembrane tryptic protease, matriptase. Because ENaC-mediated dehydration contributes to cystic fibrosis (CF), prostasin and matriptase are potential therapeutic targets, but their catalytic competence on airway epithelial surfaces has been unclear. Seeking tools for exploring sites and modulation of activity, we used recombinant prostasin and matriptase to identify substrate t-butyloxycarbonyl-l-Gln-Ala-Arg-4-nitroanilide (QAR-4NA), which allowed direct assay of proteases in living cells. Comparisons of bronchial epithelial cells (CFBE41o-) with and without functioning cystic fibrosis transmembrane conductance regulator (CFTR) revealed similar levels of apical and basolateral aprotinin-inhibitable activity. Although recombinant matriptase was more active than prostasin in hydrolyzing QAR-4NA, cell surface activity resisted matriptase-selective inhibition, suggesting that prostasin dominates. Surface biotinylation revealed similar expression of matriptase and prostasin in epithelial cells expressing wild-type vs. ΔF508-mutated CFTR. However, the ratio of mature to inactive proprostasin suggested surface enrichment of active enzyme. Although small amounts of matriptase and prostasin were shed spontaneously, prostasin anchored to the cell surface by glycosylphosphatidylinositol was the major contributor to observed QAR-4NA-hydrolyzing activity. For example, the apical surface of wild-type CFBE41o- epithelial cells express 22% of total, extractable, aprotinin-inhibitable, QAR-4NA-hydrolyzing activity and 16% of prostasin immunoreactivity. In conclusion, prostasin is present, mature and active on the apical surface of wild-type and CF bronchial epithelial cells, where it can be targeted for inhibition via the airway lumen.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22582115      PMCID: PMC3404626          DOI: 10.1152/ajplung.00303.2011

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  40 in total

1.  Prostasin is a glycosylphosphatidylinositol-anchored active serine protease.

Authors:  L M Chen; M L Skinner; S W Kauffman; J Chao; L Chao; C D Thaler; K X Chai
Journal:  J Biol Chem       Date:  2001-03-26       Impact factor: 5.157

2.  Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis.

Authors:  Karin List; Christian C Haudenschild; Roman Szabo; WanJun Chen; Sharon M Wahl; William Swaim; Lars H Engelholm; Niels Behrendt; Thomas H Bugge
Journal:  Oncogene       Date:  2002-05-23       Impact factor: 9.867

3.  The mouse frizzy (fr) and rat 'hairless' (frCR) mutations are natural variants of protease serine S1 family member 8 (Prss8).

Authors:  Damek V Spacek; Amarilis F Perez; Katelynn M Ferranti; Lillya K-L Wu; Daniel M Moy; David R Magnan; Thomas R King
Journal:  Exp Dermatol       Date:  2010-02-25       Impact factor: 3.960

4.  Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation.

Authors:  Sarah Netzel-Arnett; Brooke M Currie; Roman Szabo; Chen-Yong Lin; Li-Mei Chen; Karl X Chai; Toni M Antalis; Thomas H Bugge; Karin List
Journal:  J Biol Chem       Date:  2006-09-15       Impact factor: 5.157

5.  Prostasin: a possible candidate gene for human hypertension.

Authors:  Haidong Zhu; Dehuang Guo; Ke Li; Weili Yan; Yuande Tan; Xiaoling Wang; Frank A Treiber; Julie Chao; Harold Snieder; Yanbin Dong
Journal:  Am J Hypertens       Date:  2008-06-26       Impact factor: 2.689

6.  Alpha(1)-antitrypsin inhibits epithelial Na+ transport in vitro and in vivo.

Authors:  Ahmed Lazrak; Izabella Nita; Devipriya Subramaniyam; Shipeng Wei; Weifeng Song; Hong-Long Ji; Sabina Janciauskiene; Sadis Matalon
Journal:  Am J Respir Cell Mol Biol       Date:  2009-01-08       Impact factor: 6.914

7.  Prostasin expression is regulated by airway surface liquid volume and is increased in cystic fibrosis.

Authors:  Mike M Myerburg; Erin E McKenna; Cliff J Luke; Raymond A Frizzell; Thomas R Kleyman; Joseph M Pilewski
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-02-29       Impact factor: 5.464

8.  Mouse prostasin gene structure, promoter analysis, and restricted expression in lung and kidney.

Authors:  George M Verghese; Z Y Tong; Vikash Bhagwandin; George H Caughey
Journal:  Am J Respir Cell Mol Biol       Date:  2003-09-04       Impact factor: 6.914

9.  Mutation G827R in matriptase causing autosomal recessive ichthyosis with hypotrichosis yields an inactive protease.

Authors:  Antoine Désilets; François Béliveau; Guillaume Vandal; François-Olivier McDuff; Pierre Lavigne; Richard Leduc
Journal:  J Biol Chem       Date:  2008-02-08       Impact factor: 5.157

10.  The epidermal barrier function is dependent on the serine protease CAP1/Prss8.

Authors:  Céline Leyvraz; Roch-Philippe Charles; Isabelle Rubera; Marjorie Guitard; Samuel Rotman; Bernadette Breiden; Konrad Sandhoff; Edith Hummler
Journal:  J Cell Biol       Date:  2005-08-01       Impact factor: 10.539

View more
  6 in total

1.  Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.

Authors:  Steven M Rowe; Ginger Reeves; Heather Hathorne; G Martin Solomon; Smita Abbi; Didier Renard; Ruth Lock; Ping Zhou; Henry Danahay; John P Clancy; David A Waltz
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

2.  Mutational tail loss is an evolutionary mechanism for liberating marapsins and other type I serine proteases from transmembrane anchors.

Authors:  Kavita Raman; Neil N Trivedi; Wilfred W Raymond; Rajkumar Ganesan; Daniel Kirchhofer; George M Verghese; Charles S Craik; Eric L Schneider; Shilpa Nimishakavi; George H Caughey
Journal:  J Biol Chem       Date:  2013-02-27       Impact factor: 5.157

3.  Divergent Inhibitor Susceptibility among Airway Lumen-Accessible Tryptic Proteases.

Authors:  Shilpa Nimishakavi; Wilfred W Raymond; Dieter C Gruenert; George H Caughey
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

4.  Matriptase shedding is closely coupled with matriptase zymogen activation and requires de novo proteolytic cleavage likely involving its own activity.

Authors:  Chun-Che Tseng; Bailing Jia; Robert Barndt; Yayun Gu; Chien-Yu Chen; I-Chu Tseng; Sheng-Fang Su; Jehng-Kang Wang; Michael D Johnson; Chen-Yong Lin
Journal:  PLoS One       Date:  2017-08-22       Impact factor: 3.240

5.  Proteolytic cleavages in the extracellular domain of receptor tyrosine kinases by membrane-associated serine proteases.

Authors:  Li-Mei Chen; Karl X Chai
Journal:  Oncotarget       Date:  2017-04-10

6.  Human cancer cells retain modest levels of enzymatically active matriptase only in extracellular milieu following induction of zymogen activation.

Authors:  Li-Ling Chu; Yuan Xu; Jie-Ru Yang; Yi-An Hu; Hsiang-Hua Chang; Hong-Yu Lai; Chun-Che Tseng; Hue-Yu Wang; Michael D Johnson; Jehng-Kang Wang; Chen-Yong Lin
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.